MRI contrast agent developer Epix Medical has named Gregg Mayer vice president of marketing. Mayer will oversee the development and implementation of a strategic plan for the commercial launch of the company’s MS-325 MRI contrast agent, which is in
MRI contrast agent developer Epix Medical has named Gregg Mayer vice president of marketing. Mayer will oversee the development and implementation of a strategic plan for the commercial launch of the companys MS-325 MRI contrast agent, which is in phase II clinical trials for peripheral vascular disease, coronary artery disease, and breast cancer (SCAN 1/14/98). Mayer joins Cambridge, MA-based Epix from a position as worldwide marketing manager at pharmaceutical firm Chiron Diagnostics. He has also been employed by Abbott Diagnostics.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.